IL1B and non-small cell lung carcinoma: The exploratory analyses performed in CANOPY-1 and CANOPY-N provide insights into the TME features in patients who received IL-1β blockade, which could help identify patients with NSCLC who may benefit from the addition of IL-1β inhibition to an ICI.